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With varying degrees of enthusiasm, researchers and decision-makers support the use of
telemedicine. Forms of telemedicine are appearing in health-care delivery, and are often in-
tegral to transforming health-care information technology. Despite this, the appropriate role
of telemedicine in the delivery process remains ambiguous, at least partly because of its un-
certain impact on costs. Cost savings and benefits are often suggested by the logic of its im-
pact on health care and by the promise of technology, but definitive information on the costs
and benefits remain elusive. The objectives of this paper are to review the state of telemed-
icine cost research, to examine major issues affecting the yield from this research, and finally
to recommend strategies for improving future research. As this paper demonstrates, the pro-
ductivity of telemedicine cost studies suffers from an under-utilization of appropriate pro-
gram evaluation and economic methods. This review of telemedicine cost literature will ap-
praise telemedicine cost studies and their findings within a broad analytic framework.
Telemedicine cost studies will be assessed on their methods of statistical inference, use of
critical economic concepts, and contextual definition for the determination of costs and ben-
efits.
TG Reardon & Associates, LLC, Ann Arbor, Michigan.
OBJECTIVES AND BACKGROUND
RESEARCHERS HAVE YET TO ESTABLISH either asufficient body of findings or a vision for
understanding telemedicine costs. Systematic
literature reviews report a few useful cost find-
ings along with many inadequate methods 
of inference. Most notable is the absence of 
randomized, controlled trials. But even among
studies meeting minimal methodological crite-
ria, studies suffer from poor use of analytic
techniques in economics and inadequate docu-
mentation.
Difficulties in cost analysis have been attrib-
uted to problems in evaluating new programs,
low levels of use, and rapidly changing tech-
nology. A few authors have called into ques-
tion the usefulness of traditional tools of eco-
nomic evaluation and have proposed new
conceptual frameworks.1 Despite these ap-
praisals, there are no detailed assessments or
proposed strategies for addressing the low pro-
ductivity of telemedicine cost analysis, whether
from inadequate use of theory, the difficult na-
ture of applying economics in this field, or lim-
ited expertise in the requisite methodology.
Clinical research design and statistical infer-
ence have guided telemedicine cost evalua-
tions. The methodological benchmark has 
compared assessments of alternatives, and the
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strongest evidence and highest-quality find-
ings come from randomized, controlled trial
(RCT) designs. Systematic reviews of telemed-
icine literature largely are based on criteria
from classic RCT, and comparisons are among
alternative interventions as measured by costs
and benefits. But although the RCT model is
appropriate for assessing clinical effectiveness,
the evaluation of telemedicine programs has
fundamentally different purposes, standards
for judging causality, logistical constraints, and
implications from major threats to validity.2
Hence different methods may enable more ef-
fective program cost evaluations.
RCT guarantees little when applied to most
telemedicine program evaluation, which faces
different constraints from clinical research. Re-
search on pharmaceutical and biological de-
vices, for example, depends on the use of RCT
methods to infer causality. On the other hand,
the purpose of telemedicine cost evaluation is
to support program and policy decision mak-
ing.
The overall quality and success of a program
evaluation depends on understanding and ap-
plying findings to decision-making contexts
and needs. The key methodological challenge
in telemedicine cost evaluation is to identify 
the decision-making information requirements
and to depict the decision framework that de-
fines the contextual validity of findings. This
issue was argued in a recent position paper of
the American Evaluation Association (AEA),
RCTs are not always best for determining
causality and can be misleading. RCTs ex-
amine a limited number of isolated factors
that are neither limited nor isolated in nat-
ural settings. The complex nature of
causality and the multitude of actual in-
fluences on outcomes render RCTs less 
capable of discovering causality than de-
signs sensitive to local culture and condi-
tions and open to unanticipated causal
factors.2
Consequently, although selecting a method-
ology that achieves internal validity remains
important in cost evaluations, methods that fit
the specific problem context and decision-mak-
ing needs are equally important.
In addition, the effective interpretation and
generalization of program cost evaluations rely
on different tools and applications of concep-
tual schema as compared with those of clinical
research and most cost evaluations of drugs
and devices. Telemedicine programs are highly
heterogeneous interventions, with complex
sets of input, output, and context factors. In-
terpreting the data and findings on telemedi-
cine program costs requires insight into the
health-care delivery processes that generate the
data. Interpretation, integration of findings,
and generalizations often require insights from
health-care delivery and economic theories.
Meaning and differences in findings may not
become apparent until viewed within a con-
struct, such as health production.
At the same time, the specific uses of pro-
gram cost evaluations shape the results and the
applicability of findings. For example, cost
evaluation may focus on providing results for
a health-care organization or a system of care,
or they may be intended for general applica-
tion. Different research methods may provide
equally valid information on a question, but the
measures and control of contextual factors may
require different evaluation methods. A review
of research studies needs to incorporate the in-
tended use of the evaluation. Different strate-
gies may be needed to synthesize disparate
findings.
Accordingly, telemedicine cost evaluations
and reviews of this literature have not paid at-
tention to the unique purposes, needs, and
methods of program cost evaluation, nor have
they focused on non-RCT or economic method-
ologies. Program cost evaluations involve
matching analytic methods to the purpose and
constraints of the evaluation, identifying the
role and characteristics of decision-making
frameworks, and using appropriate economic
concepts for interpreting program findings.
Each of these components of the analytic struc-
ture may be momentous in determining the
value of a study. Although trade-offs exist in
the use of optimal strategies, rigid adherence
to strong methods of determining causality
may make studies meaningless because of as-
sociated limitations in contextual validity. The
productivity of telemedicine cost studies suffer
from an under-utilization of appropriate pro-
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gram evaluation and economic methods in
their design and assessment. First, however,
these elements of cost evaluation are applied in
the literature, and the methods of selecting the
literature are described.
ELEMENTS OF COST EVALUATIONS OF
HEALTH-CARE SERVICES
A review of the major analytic components
of health-care services cost evaluations pro-
vides an overview of the economic concepts,
cost analysis decision framework, and methods
of inference that affect the quality and produc-
tivity of telemedicine cost research. This over-
view guides the subsequent identification, se-
lection, and review of the telemedicine cost
literature.
Cost evaluations of health-care services dif-
fer in their purpose. Information about costs
may be needed in organizational resource plan-
ning; funding agencies may require evalua-
tions to justify expenditures; or health-care sys-
tem policy makers may be considering broad
deployment of a technology. But at the core of
each cost evaluation is the analytic contribution
of economics, a comparison of alternatives
based on the concept of “opportunity costs,”
defined in the MIT Dictionary of Modern Eco-
nomics as “the value of resources given up
through a decision.”56 The essence of the cost
evaluation is identifying the alternative that
provides the greatest value in relation to the
opportunity costs. This may be described in
three basic steps:
1. Identify and aggregate the costs of each
health-care alternative.
2. Identify and aggregate valued outcomes
of each alternative.
3. Compare the aggregated relative, “value
for cost,” for each alternative (e.g., such as
the ratio of costs to changes in quality-ad-
justed life years attributable to an inter-
vention).
This process seems simple; however, most of
the debate around telemedicine cost analysis
comes from difficulties in implementation, and
here economic theory only provides broad
guidance. The usual errors and shortcomings in
the telemedicine cost literature may be attrib-
utable to its deceptive conceptual simplicity.
Implementation of a cost analysis requires a
well-defined decision framework that consists
of objectives, resources used, definitions of out-
puts, and a context of the decision making, such
as timeframe. The relative significance of each
these issues in determining the quality of a
study depends on program characteristics and
types of telemedicine.
Although the specification of telemedicine is
grounded in economic concepts, it often de-
pends on a broad, multidisciplinary under-
standing of health services delivery. Complex
interventions of telemedicine, concepts of sys-
tems analysis, organizational decision making
and strategy, and health-care behavior may be
critical for identifying and understanding the
value and cost of the telemedicine.
Differences of opinion exist regarding the
value of applying economic concepts to cost
evaluation. Some variations in methods may
arise because of differences in objectives, as-
sessments of the literature, or simply due to
multiple, equally acceptable approaches on
some issues. On the other hand, conformity in
an approach facilitates assessments of literature
and provides common utility from a cost study,
especially if the study fits within broader re-
search or health-care policy objectives. Con-
sensus definitions and methods in several ar-
eas leverage the cost literature and provide
collective value. Consensus guidelines are
making their way into recommended cost eval-
uations, and they provide an import element in
assessing telemedicine costs.
The following sections provide an overview
of the cost evaluation that affects the quality of
the telemedicine cost literature. Economic con-
ceptual issues, the decision framework, related
considerations of methodological inference,
and the role of cost guidelines as they affect the
quality of telemedicine cost studies are sum-
marized. These materials will shape the subse-
quent review of the telemedicine literature.
Economic concepts
Economic theory, as applied to cost evalua-
tion, generally is not a basis for prediction, but
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it provides concepts and a structure for identi-
fying and developing those measures of inputs
and outputs that define program performance.
Primarily, the concepts of economic theory of
choice constitute a reference for researchers de-
veloping observable measures of costs and ben-
efits, and selecting the most appropriate cost
evaluation model, such as cost–benefit analysis
(CBA) and cost effectiveness analysis (CEA).
Otherwise, for program cost evaluations, eco-
nomic theories of organization and production
may help clarify appropriate definitions; iden-
tify appropriate aggregations of costs and ben-
efits, and interpret expected impact or findings.
Economic costs and benefits
The most important role of economic theory
in cost evaluation is in guiding the identifica-
tion and measurement of economic costs and
benefits. In particular, the concept of costs, de-
fined as an opportunity cost in the economic
theory of choice, provides the conceptual foun-
dation for defining costs as the value placed on
those resources given up by a decision maker
when making a specific choice. As such, costs
identified in an economic evaluation are sub-
jective, being defined distinctly from the per-
spective of a single decision maker.
However, costs, or components of costs, may
be estimated through such metrics as market
prices. A parallel concept may be applied to the
valued gains of a decision that define benefits.
Thus, among choice alternatives, a comparison
is made of the estimates of a decision maker’s
opportunity costs relative to the value of out-
comes. The measurement of costs is the nega-
tive aspect of choice, or the value of what is
given up, and the measurement of benefits is
the positive value placed on gains. The as-
sumed preference is for the greatest value of
outcomes relative to opportunity costs for the
decision maker.
Of course, whereas the concept is deceptively
reasonable and easy to grasp, the implementa-
tion is exasperatingly complex. To begin, the
analyst must carefully define the decision
maker and the intervention or decision under
consideration and its alternatives. Economic
concepts may help define relevant features of
a telemedicine intervention, but mostly the de-
scription and detail of a program are distinct
from the core application of economic concepts
in the cost evaluation. These issues of program
definition are addressed in a subsequent sec-
tion of this review. This task aside, however,
the challenge lies in distinguishing inputs and
outputs and assigning appropriate costs and
benefits where they are tied to the subjective
assessments of the decision maker.
The measurement of costs begins with an
identification of the resources “given up” as a
result of a choice, by implementing a telemed-
icine activity or program. Here, the question
that needs careful consideration is whether im-
plementation of the telemedicine program re-
quires new resources or expenditures (e.g., con-
struction) or the commitment of resources (e.g.,
existing facilities) that could be used for other
purposes elsewhere. The concept of opportu-
nity cost distinguishes the relevant cost for the
evaluation in that the resources used are a con-
sequence of the decision. For example, the in-
stitutional overhead of a program may be an
accountant’s cost, but not necessarily an eco-
nomic cost because additional commitment of
overhead may not be required with the imple-
mentation of telemedicine. Of course, this as-
sessment of costs depends on the timeframe of
the decision. In the short run, there may not be
an opportunity cost for the facility, but long-
run facility costs may be incurred. Hence, this
assessment of program costs must consider the
relevant timeframe.
Once opportunity costs are identified for a
telemedicine program, the analyst is then able
to address the related question on the value
of the resources. Again, the value assigned to
resources is defined from the perspective of
the decision maker. Values may be easily as-
signed to some resources, as market prices of-
ten reasonably represent the value of re-
sources such as equipment, manpower, etc.
On the other hand, resource costs of volun-
teer labor and patient travel may not be eas-
ily determined. Nonetheless, an analytic ob-
jective should identify all resource costs
(market and nonmarket) that accrue to a de-
cision maker as a result of the program. A
common metric of value must be used to pro-
duce an aggregate measure of costs for each
program alternative.
ASSESSING TELEMEDICINE COSTS 351
5690_10_p348-369  7/6/05  2:17 PM  Page 351
At the same time, each program choice, such
as telemedicine or its alternative, results in out-
comes as well as costs. Hence, the analysis must
identify all of the important outcomes or gains
from each intervention.
Identifying and then measuring the value or
benefits of a telemedicine intervention may be
considered the complement of determining the
opportunity costs of resources, but this task in
the evaluation assessment is often more chal-
lenging. In contrast to input costs, market
prices are usually not available for the benefits
derived from the health-care program. More-
over, the outputs themselves, such as a suc-
cessful treatment or improvements in health
frequently are not easily defined, identified, or
measured.
Telemedicine programs may create new out-
comes of care or change outputs or outcomes.
These benefits of telemedicine are often diffi-
cult to identify, partly because detecting them
depends on our expectations or knowledge of
effects on health or other outcomes. Also, de-
tecting benefits may depend on timing, with
some benefits only becoming apparent at a time
in the future. Then, again, whether an outcome
is a benefit may depend on the perspective of
the decision maker or stakeholder. The decision
maker may be interested in the ability of
telemedicine to provide visits or treat episodes
of care, but not in the longer-term effects on
health.
But even with outcomes identified, a formi-
dable task remains in assigning value to the
outcomes of telemedicine and aggregating the
sum of benefits for all outcomes. From the per-
spective of economic analysis the ideal is to
evaluate all outcomes with a common mone-
tary metric. These could then be aggregated
and compared with costs for each alternative.
This type of assessment, CBA, is the preferred
method of evaluating alternatives because it fa-
cilitates the most direct and ideal implementa-
tion of the economic evaluation paradigm, and
the broadest consideration of cost and benefit
tradeoffs, allowing comparisons with all simi-
larly evaluated choice alternatives. Yet, the ap-
plication of CBA is often difficult, especially in
health care, because of the need to identify,
measure, summarize, and compare outcomes
that are not usually assessed through the mar-
ket-based exchange. In particular, there is a
general reluctance to assign a value to life or
health, at least in such a way as to make it com-
parable to values placed on non-health-care
commodities. Consequently, CBA that do not
rely on monetary assessments of benefits are
more often used in health-care cost evaluation.
Several alternative methods of CBA have
evolved. Most are prominently distinguished
by their methods of establishing and aggregat-
ing benefits, or valued outcomes. Each may be
appropriate, depending on the needs of the an-
alyst and the trade-offs. More than 10 govern-
ment and industry organizations have devel-
oped health-care cost-analysis guidelines in
which several different types of cost evalua-
tions are recommended.3 Issues associated
with several of the most common cost-analytic
methods in telemedicine are briefly described
in Appendix 1.
Among the half dozen types of cost evalua-
tion used frequently in health-care services re-
search, CEA is most prominent. As described
in the appendix, whereas costs are monetary in
a CEA, personal health-care outcomes are re-
ported in nonmonetary terms, such as changes
in blood pressure, or longer-term outcomes,
such as improvements in quality-adjusted 
life years (QALYs), where years of life are
weighted by health-related quality measures.4
A resulting program assessment metric such as
“cost per QALY” provides a common currency
that is especially helpful for comparing health-
care technologies.5
Of course, each cost and benefit method has
advantages and disadvantages with implica-
tions for measurements of benefit, potential
comparisons among alternatives, and types of
outcomes that can be captured in the analysis.
The different methods, as well as details in this
implementation, determine the range and
types of effects captured in the analysis, as well
as the potential for comparisons among alter-
natives. For example, selecting episodes of ill-
ness as the outcome of a CEA evaluation lim-
its the potential to identify the effects of
telemedicine on preventing new episodes of ill-
ness. Using visits or virtual visits as the out-
come ignores the potential of telemedicine to
treat episodes with fewer provider contacts, or
fewer hospitalizations.
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Cost minimization analysis (CMA) of tele-
medicine generally ignores any potential for
telemedicine to affect health-related outcomes,
because CMA strictly focuses on cost-related
benefits of the technology.
In summary, understanding cost–benefit
concepts applied to the economic theory of
choice is fundamental to both appropriate de-
sign and interpretation of telemedicine cost
evaluations. This affects the identification and
measurement of appropriate inputs and out-
puts of telemedicine and its alternatives. The
concepts and the selection of a cost and bene-
fit method constrain the potential inference
from and the interpretation of findings.
Production functions in telemedicine 
cost evaluations
Compared with the economic theory of
choice, other areas of economic theory are far
less pivotal in health-care program cost evalu-
ation. However, economic concepts of produc-
tion appear likely to contribute to the design of
telemedicine cost evaluation. This theory also
has the potential to spur the development of a
body of telemedicine production knowledge
and models with predictive content.
Berki first proposed the use of an economic
production function to structure our under-
standing of telemedicine, stating “ . . . the fun-
damental effects flowing from the introduction
of telemedicine will be changes in the process
of production outputs as well as changes in the
outputs themselves.”6 His detailed develop-
ment of an economic production function of
telemedicine was employed to generate insight
and questions on the implications of telemedi-
cine and the design of telemedicine economic
research. In particular, he identified the need
for greater specificity in types of telemedicine
and their outputs when attempting to analyze
telemedicine costs. He also identified the need
to address telemedicine as being embedded
within a health-care system.
Although not providing a predictive theory
of costs, Berki emphasized the use of telemed-
icine production analyses to identify an exten-
sive range of potential inputs and outputs. He
also identified the complexity of cost research
design and interpretation. Economic produc-
tion theory provides a logical structure to iden-
tify and evaluate cost determinants, resources
that affect costs, and the associated outcomes.
It identifies both potential factors and logic re-
lated to the transformation from resources into
such outcomes as access, health, and satisfac-
tion. Hence, the body of telemedicine cost find-
ings may be more easily understood through
this framework, which, when combined with
specific findings, may improve future research
and lead to predictive models for telemedicine
cost research.
Cost assessment framework
Biomedical devices may be described
through a set of technical specifications; how-
ever, the content of a telemedicine program is
less easy to define. Most often, telemedicine
programs are described through areas of med-
ical specialty or location of care. These attri-
butes, however, are insufficient for specifying
production inputs and likely outputs. More-
over, contextual factors of delivery programs,
such as the boundary between teleradiology
and standard radiology, are much more 
ambiguous. Consequently, additional descrip-
tions of telemedicine programs are often
needed. The question is what constitutes the
program? What are the critical dimensions that
facilitate more homogeneous groupings or ad-
justments for comparison of findings?
Some of the useful attributes for characteriz-
ing telemedicine programs are those that de-
termine the use and value of program inputs
or outputs, or that characterize assessments of
opportunity costs. These attributes may be
viewed as a cost assessment framework, which
is not a well-defined algorithm or theory, but
rather a description of a telemedicine program
that is situationally relevant in identifying and
defining costs and benefits. For example, such
characterization reveals how a program is de-
fined and the decision-making time horizon,
both of which affect costs for the stakeholder.
The decision maker’s objectives, delineation of
the boundaries between the intervention and
context, and identification of a target audience
for use of research results are major underly-
ing assumptions that characterize the cost eval-
uation problem.
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The cost assessment framework as defined in
Table 1 is closely related to components used
in defining CEA by the United States Public
Health Service (USPHS) Consensus Panel.7 The
major dimensions of this framework help as-
sess telemedicine cost-evaluation design and
interpretation.
Program objectives and study purpose
A principal aim of telemedicine cost evalua-
tion is to provide decision makers with infor-
mation on costs of alternatives decisions. This
requires an accurate understanding of objec-
tives so as to obtain a precise identification and
valuation of what is given up and gained as the
result of an action. For example, a program
with a short-term treatment objective will in-
cur different costs and benefits than one focus-
ing on prevention. Without sufficient knowl-
edge of the decision-making objective, the
empirical research and analysis may not be rel-
evant. That is, precise evidence on the wrong
question is most often not helpful. Conse-
quently, it is often useful to have a pre-evalu-
ation assessment of the decision maker’s ob-
jectives. Careful consideration of objectives
may be warranted when interpreting findings
in the telemedicine literature.
Notably, the issue of program objectives is
related to but separate from that of the decision
maker’s perspective. Different types of decision
makers, such as the patient, provider, payer,
and society at large, may have different objec-
tives for a program and different values as-
signed to benefits. But these groups are also
likely to incur different costs and benefits from
the program, even if they agree on the same
program objective.
This difference in perspective results in dif-
ferent costs and benefits among the stakehold-
ers, and sometimes may result in differing 
incentives for program participation. The ap-
propriate perspective for an evaluation will de-
pend on the purpose of the evaluation. On the
other hand, many researchers advocate the in-
clusion of the societal perspective (where all
program costs and benefits are included in the
CBA, regardless of who incurs or accrues them)
in reporting results. The intent here is to facil-
itate comparability across studies.
At the same time, the primary purpose of
telemedicine cost evaluation is to support
health-care policy and organizational decision
making. For this purpose, a cost assessment
framework may guide the evaluation, but for
that evaluation researchers may also subscribe
to a larger role of ongoing knowledge building
by making study results usable for a broad
population of stakeholders with similar objec-
tives. Here, simply the intended scope in the
generality of findings may affect the methods
of evaluation. For example, an evaluation may
provide valid and generalizable results at a lo-
cal or national level. Variations in international
prices, population preferences, and health sys-
tem efficiency, however, may undermine cross-
country generalizations.8 The challenge be-
comes one of the research tradeoffs required to
address contextual factors that influence the
generality of results. Less powerful findings lo-
cally may be sacrificed for the power of broad
generalization.
Telemedicine program definition and context
Telemedicine refers to a wide range of activ-
ities providing health care at a distance. These
include remote monitoring, where capabilities
are largely defined by device specifications;
medical encounters that may be defined by en-
abling devices; and complex delivery pro-
grams, such as virtual hospitals that employ a
complex mix of technologies and innovative
processes. Thus, telemedicine interventions
may include hardware and software technol-
ogy, a clinical process, and a broad system of
health-care delivery.
With device-oriented telemedicine, the defi-
nition of the program, its functional capabili-
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ties and resources, and the relevance of any
contextual factors are more easily identified. In
contrast, as telemedicine becomes a complex
program of activities with different resources
and multiple outcomes, the heterogeneity of
telemedicine capabilities, capacities, and re-
sources create a substantial challenge to be gen-
eralized from an evaluation. Closely integrated
technologies, such as information technology
systems and contextual factors, are likely to
have dependencies in the system of care that
are not easily separated from core telemedicine
capabilities.
At the same time, telemedicine-oriented sys-
tems of care are more likely to provide needed
economies of scale, joint gains from technology,
and manpower knowledge efficiencies. In ad-
dition, the complexity of systems and activities
related to telemedicine systems are likely to
make program performance less determined by
technical capabilities and increasingly depen-
dent on management efficiencies and incen-
tives, as has been discovered with information
technology in general.9 Hence, the defining at-
tributes of a promising telemedicine interven-
tion are likely to change as applications shift
from narrowly defined, technically oriented
clinical telemedicine capabilities to reliance on
systems of information technology with be-
haviorally defined production processes.
The result is that different approaches and
concepts may apply to cost evaluation of de-
vice-dominant telemedicine as compared with
system- or activity-dominant telemedicine pro-
grams. Basic comparisons of alternatives that
fit the evaluation paradigm appear to be less
appropriate for cost evaluations of less techno-
logically dominant and complex telemedicine
systems of care. The cost impacts of telemedi-
cine systems may be determined by a set of con-
textual factors, some of which may be identi-
fied through economic theories of organization
and competition.
Methods of inference
RCTs constitute the most powerful method-
ology for testing the impact of a medical inter-
vention, procedure, or medication. Medicine
has been well served by RCTs and cost-effec-
tiveness/cost-utility evaluations of pharma-
ceuticals and medical devices have been quite
successful by employing RCT methods of in-
ference. Nonetheless, whereas RCT methods
may be good for evaluating telemedicine cost,
other methods of statistical analysis may be
warranted and even preferred.
In contrast to telemedicine, several areas 
of evaluation accept alternative methods for
demonstrating causality though the rationale
may not be without some debate. Of course,
medical research has the strongest tradition of
randomized experimental design for causal as-
sessment, and perhaps because of this, non-
RCT methods have had limited use in evaluat-
ing telemedicine costs. Several arguments for
using alternative methods of inference appear
credible in relation to program cost evaluation,
including when:
• Threats to external validity transcend the
RCT contribution to internal validity,
• Relationships between the intervention and
context cannot be disentangled through ran-
dom assignment,
• RCTs are not feasible or the additional con-
fidence in outcomes provided by RCTs is
economically justified,
• Question of interest is not an unbiased esti-
mate of program costs in a population but
an estimate of costs in an uncontrolled set-
ting (i.e., when self-selection is allowed).
The strength of RCT derives from ensuring
the internal validity of findings.10 But impor-
tant determinants of costs, such as organiza-
tional competence, factor prices, and health
system policy, are difficult to randomize, and
they may have a more significant impact on
cost than the intervention. Hence, the RCT find-
ings from telemedicine programs cost evalua-
tions may have limited value to decision mak-
ers who are concerned about the overwhelming
effects of their context. Moreover, when the
performance of telemedicine is determined by
a system of variables, such as those involved in
health-care production, or conditional on fac-
tors, such as managerial incentives, contextual
effects may be impossible to disentangle from
contextual factors. In neither case do RCT
methods provide the best information for the
decision.
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For some types of telemedicine costs ques-
tions, decision makers may not be interested in
the unbiased estimates of costs. For example, a
third-party payer may be interested in the cost
of self-selection biased program, i.e., program
costs when patients have self-selected. Selec-
tion and choice are important components in
the design of a health-care delivery system, so
unbiased cost-effectiveness may not be useful
without knowing the cost bias of choice.
To summarize, the methodological question
is to determine the appropriate or “cost-effec-
tive” methods of inference, matching the eval-
uation design to the evaluation’s purpose, re-
sources, and stage of development.
Cost analysis guidelines
Guidelines are increasingly available for con-
ducting, evaluating, and synthesizing health-
care research. They provide a powerful tool for
improving the quality and comparability of
studies. However, although economic cost
analysis is tied to an economic theory of choice,
there is room for considerable latitude and dif-
ferences of opinion in applications. For exam-
ple, standardizing definitions would improve
the comparability of studies. Errors and
methodological limitations of cost analysis are
reported throughout the literature. Nonethe-
less, guidelines are designed to improve the
quality of research in this area.
Spurred by their potential to provide a sig-
nificant collective value for health-care cost re-
search, health-care cost analysis guidelines
have evolved rapidly.3,11 A few sources focus
on assessing and improving quality of evalua-
tion studies.12 Most notably, the Cochrane Col-
laboration provides guidance for systematized
assessment and synthesis of study evidence.12
Other groups have developed guidelines that
promote consensus or preferred definitions
and methods for research, and less explicitly at-
tempt to determine evaluative standards. At
least 10 sets of formal and informal guidelines
dedicated to health care cost analysis, mostly
related to pharmaceuticals and devices, have
been developed by government and industry
organizations. Perhaps the most detailed of
these are the USPHS Consensus Panel guide-
lines that demonstrate a particular interest im-
proving the comparability of studies.7 The Con-
sensus Panel provides a theoretically consistent
cost assessment framework for: (1) defining a
cost or resource allocation decisions, including
decision-making objectives and defining the
program or intervention; (2) determining the
decision model of costs and benefits; (3) speci-
fying data and measures; (4) performing ap-
propriate statistical, modeling, and sensitivity
analyses; and (5) reporting results understand-
able by decision makers and researchers.
Notable improvements in compliance with
key guidelines have been reported since 
publication of the consensus panel recommen-
dations.13 On the other hand, analysis of pub-
lished cost analysis guidelines found agree-
ment for about 75% of methodological aspects.3
Disagreement was found in the recommended
choice of perspective, the types of resources
considered, and costs that should be included
in the analysis. Partly, the differences in the
guidelines appear to stem from differences in
research objectives and associated technical is-
sues. As a recent assessment of evaluative 
systematic reviews concluded, “Methods for
assessment of methodological quality by sys-
tematic reviews are still in their infancy, and




The status of telemedicine cost research is
shaped by research findings, methodologies,
and the resulting conceptual understanding of
telemedicine costs. To this end, this section of-
fers an approach and selection process for ob-
taining an accurate representation of this liter-
ature.
Several authors have used formal guidelines
in conducting systematic literature searches in
reviewing of telemedicine cost evaluations.15–20
Typically, these searches have used topical key-
words to identify articles, and then explicit 
criteria on scientific merit for including or ex-
cluding studies in the review, with the objec-
tive of providing an efficient and unbiased es-
timate of costs and benefits. This paper builds
on these earlier works, but not simply by
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adding the recent months of findings. Taking
advantage of these earlier efforts, the results of
earlier reviews and key studies are combined
with newly identified studies. The emphasis of
this assessment is on the conceptual and
methodological rigor in cost studies, on the
usefulness of identified cost issues, on research
methods and strategies, and on conceptual in-
terpretation. The concepts and methods dis-
cussed in previous sections of this paper21 are
used to guide the following search, selection,
and review.
Still, identifying the boundaries for selecting
articles remains a formidable task, which is es-
pecially apparent in terms of the conceptual
ambiguities surrounding telemedicine costs.
Activities that may be considered telemedicine
continue to blend applications of information
and communications technologies. Of course,
the history of telemedicine research has been
characterized by substantive debate on defini-
tions, and this continues to evolve with tech-
nology. As a result, the use of a defined set of
telemedicine keywords in selecting literature
may easily omit relevant studies, but the most
ambitious expansion of terms begins to capture
an unmanageable number of studies.
An efficient alternative for selecting and
reading abstracts produced by the most ex-
pansive set of keywords evolved from first con-
sidering studies identified through previous
systematic reviews and then using keyword
and database selection strategies to augment
the literature. This approach may be best de-
fined as iterative triangulation. That is, first
previous reviews and standard initial sets of
telemedicine keywords were used to create a
database of abstracts for review. These were
used to create a database of keywords, which
resulted in overlapping sets of literature. Sets
of prominent and seemingly relevant key-
words were examined to identify additional ar-
ticles, but investigating the detailed subsets of
articles depended on the initial payoff in the
discovery of new articles.
At the same time, significant references were
also identified from the lists of references in the
original articles. While the primary focus was
on telemedicine cost literature, other promi-
nent databases in the literature were included,
such as health-care technology assessment
(HTA) and health-care information technology
(HIT) (Table 2). These searches were guided
largely by the need for further considering sig-
nificant issues in the telemedicine cost litera-
ture.
The database of resulting articles consisted
of studies identified through electronic
searches and manual scans of both published
and unpublished studies, resulting in a data-
base of 1,430 telemedicine articles (Table 3). Ab-
stracts for each of these were reviewed. Among
these articles, abstracts that indicated cost anal-
ysis with empirical data, or appeared to have
rigorous or unique cost analysis research meth-
ods were selected for further consideration.
Finally, a database of studies based on stan-
dard telemedicine keywords, related analytic
area keywords, and all related articles was con-
structed. Software was used to create and map
clusters of keywords, which were inspected 
to identify unrevealed telemedicine related
groups of studies. Clustering analyses of key-
words associated with over 9,000 articles were
evaluated to establish consistency across selec-
tion methods and significant omissions in top-
ical and methodological areas of telemedicine
costs. This resulted in the identification of few
additional papers, but no new topical or
methodological areas were added to the anal-
ysis.
AN ASSESSMENT OF RESEARCH
FINDINGS AND METHODOLOGIES
The prevailing consensus is that few
telemedicine cost studies have provided eco-
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nomic results that are useful for organizational
or policy decision making in telemedicine.15,22
Research reviewers have consistently noted a
small number of useful findings,15,22,17,23 and
even these are marked by questionable use of
standard cost techniques. Hence, they contrib-
ute little to the cost evidence.15,24,25 Similarly,
but perhaps having a different perspective on
what is lacking, providers and payers continue
to express a need for cost evidence for decision
making.
Analysts have provided many explanations
for the perceived inadequacy of telemedicine
cost information. Studies have been faulted for
having small user populations or data, fledg-
ling programs with premature evaluation, 
biases due to reimbursement policy, faulty eco-
nomics, and inadequate research methodol-
ogy.18,26 In particular, the limitations of the lit-
erature have been most commonly attributed
to inadequate and insufficient use of RCT-
based studies. At the same time, at a more fun-
damental level, telemedicine cost research has
been viewed as being encumbered by its “com-
plex mix of technology and services.”15 This re-
view considers whether current telemedicine
cost evaluation concepts and methods con-
stitue a barrier to useful cost research, and
whether uses of economic theory and alterna-
tive research methods would improve the
value of output from telemedicine cost re-
search. Assessments are provided through dis-
cussions of the findings and limitations of
telemedicine cost evaluation research.
An economic interpretation of cost findings
Reviewers of telemedicine cost studies be-
moan the inadequacy of research methods and
the resulting small number of useful cost find-
ings. This conclusion is partly driven by the
standards of methodological orthodoxy, or
rigidity, for causal analysis. But, it also depends
on assumptions about how findings reflect on
the specific cost problem. In particular, RCT
methods are especially appropriate for discrete,
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TABLE 3. SEARCHED SOURCES OF LITERATURE
Type of source Sources
Published literature NLM Databases—MEDLINE (1/1976–3/2004); HSAT
EMBASE (1/1995–3/2004)
ISI Science Citation Index Expanded
ECO—An Online Computer Library Center (OCLC) collection of scholarly journals,
CINAHL—Cumulative Index to Nursing and Allied Health Literature
JEL—Journal of Economic literature
World Wide Web AHRQ: http://www.ahcpr.gov/
NHS Health Technology Assessment Programme: http://www.hta.nhsweb.nhs.uk/main.htm
NHS National Institute for Clinical Excellence (NICE): http://www.nice.org.uk/
Netting the Evidence: http://www.sheffield.ac.uk/~scharr/ir/netting
Canadian Coordinating Office for Health Technology Assessment (CCOHTA):
http://www.ccohta.ca/
Office for the Advancement of Telehealth: http://www.telehealth.hrsa.gov/
VHA Telehealth: http://www.va.gov/telehealth/
Telemedicine Information Exchange: http://tie.telemed.org/
AHRQ Evidence Based Practice Centers
Cochrane technology databases
McKinsey Global Institute: http://www.mckinsey.com/knowledge/mgi/
Conference reports HIMSS conference reports: 1995–2003
AMIA conference reports
Hand-searched Journal of Telemedicine and Telecare
journals Telemedicine Journal/Telemedicine Journal and e-Health
Journal of Health Economics
Health Economics
Value of Health
Journal of Healthcare Information Management
International Journal of Technology Assessment in Health Care
Journal of Information Systems
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well-specified interventions. Accordingly, the
research design has been to address different
types of telemedicine as distinct technologies.
This specification has been maintained in the
interpretation and integration of findings. The
notion of discrete interventions has been trans-
lated as conceptually independent of the dif-
ferent types of telemedicine findings. Often, the
assumption of conceptual independence of
telemedicine program cost findings is unnec-
essary.
The economic underpinnings of cost evalua-
tions may provide a basis for the conceptual 
integration of the seemingly disparate telemed-
icine cost results. In particular, the interpreta-
tion of cost results from telemedicine programs
may make use of the economic production con-
cepts previously discussed. Specifics on the ap-
proach used in a cost analysis may be combined
with other knowledge of medical care delivery
and economic production to synthesize find-
ings around a distinct cost principle. Accord-
ingly, the following sections attempt to make
more efficient use of telemedicine cost research
by assessing how they reflect on economic pro-
cesses that determine costs.
Cost impacts on access to a medical visits
The earliest studies of telemedicine costs con-
centrated on the cost implications of enabling
access to care. As such, studies primarily con-
sidered the costs or economic gains from re-
ductions in patient or provider time traveling
for care. These studies often involved clinical
technologies that were considered unchanged
when provided through telemedicine. For ex-
ample, for purposes of cost evaluation, the clin-
ical character of a radiological service or other
imaging service was considered to be essen-
tially identical to in-person service.
Early cost studies often implicitly or explic-
itly were presented as cost-minimization stud-
ies, but they were more unique than that. The
basic specification of the problem in these stud-
ies was to limit the telemedicine effect to the
production of access while defining the cost
structure as a trade-off between gains from re-
duced travel costs and expenditures on Infor-
mation and Communications Technology (ICT)
and personnel. Hence, high barriers to access
and specialties requiring less expensive tech-
nologies were likely to produce favorable re-
sults for telemedicine.
Using this approach, telemedicine produces
cost savings for specific populations, such as
prison inmates,26,27 sailors at sea,28 or emer-
gency cases.29,30 Hence, the potentially prohib-
itive determinant in the use of care is the cost
of travel, which can be offset by efficient use of
the ICT technology. Specialties that required
cheaper technologies, such as psychiatry, or
that easily integrated the technology in the
visit, such as dermatology, were more likely to
show savings through reduced travel costs. On
the other hand, these studies were important
only to decision makers who incurred a suffi-
cient saving from travel costs. Most notably
these included U.S. prisons, the military ser-
vices, and a number of European health-care
systems.
Of course, a reasonable conclusion is that
once the technical feasibility for telemedicine is
established, the potential for savings from
travel for patients would be expected. The ev-
idence suggests that travel-based cost savings
are feasible for a variety of telemedicine spe-
cialty applications, including teleradiology, 
teleneurology, teledermatology, and teleoncol-
ogy.29–32 However, the findings for other types
of telemedicine, such as telepsychiatry, are in-
consistent. This may be due to the fact that
some of these study designs focused on the im-
pact of telemedicine on access, whereas others
included the effect of telemedicine on clinical
efficiency. The latter is the subject of discussion
in the next section.
Clinical efficiency aside, the expected savings
in this type of telemedicine analysis are situa-
tionally dependent; that is, they depend on the
environmental context, such as general costs of
travel and technology. More importantly, once
feasibility is established, significant economic
findings are not likely through a local single-site
clinical trial. The key parameters affecting costs,
location, and price of technology are external to
the design of local clinical trials.
Costs impact on clinical efficiency
A second category of telemedicine programs
effects may be characterized as changing the
ASSESSING TELEMEDICINE COSTS 359
5690_10_p348-369  7/6/05  2:17 PM  Page 359
costs of care by affecting clinical efficiency, as
well as travel and technology. But here tele-
medicine may result in changes in the amount
or mix of resources and thereby the costs of
clinical care. Changes in clinical care processes
decrease or increase cost care. This may best be
reflected in assessing episodes of care.
This additional role of telemedicine in af-
fecting costs is significant from many perspec-
tives. First, clinical costs often have a dominant
share of total costs of care, especially for pop-
ulations without exceptional barriers in access.
Consequently, efficiency savings through tele-
medicine present a much greater opportunity
for finding savings. These clinical efficiencies
may be influenced more by patient and physi-
cian characteristics and less by local situational
factors. Moreover, and perhaps as important,
depending less on local factors allows findings
on the cost impact telemedicine to be applied
more easily to other settings. Presumed costs
savings due to the effects of telemedicine on
the production process of medical care are
more likely generalizable across settings.
Analyses of telemedicine that capture the
costs impacts of clinical efficiencies may be de-
fined implicitly or explicitly through several
features of the study design. First, the analyst
may explicitly recognize the change in the mix
or types of resources used in the clinical pro-
cess. For example, store-and-forward derma-
tology is likely to be basic change in the clini-
cal process when compared with real-time
teledermatology. Alternatively, many studies
implicitly allow for impacts on clinical effi-
ciencies through their definitions of the output.
For example, where the cost impacts are ex-
amined across multiple patient encounters or
visits, then telemedicine may affect clinical in-
puts. The number or mix of clinical visits may
be changed in the treatment of the care.
Studies of teledermatology may best illus-
trate the merit of this conceptualization in guid-
ing the integration and interpretation of find-
ings. Dermatological conditions often occur in
relatively well-differentiated episodes. Conse-
quently, telemedicine studies frequently link
multiple provider encounters. At the same
time, dermatology practice lends itself to the
use of alternative sets of resources in the pro-
duction of a telemedicine visit, such as real-
time and store-and-forward processes of care.
The result is that each of the three sources of
cost impacts may apply. But changes in the
clinical process for real-time teledermatology
are less likely to affect total costs, as compared
with store-and-forward processes.
Studies of teledermatology fit surprisingly
well within the constructed cost framework.
The cost savings of real-time and store-and-
forward teledermatology depend on the costs
of travel. But store-and-forward costs have
proven to be more variable across studies and
sensitive to specific assumption about the pro-
duction of clinical care, such as patient flow.
Moreover, although an RCT study of a Vet-
eran’s Health Administration teledermatology
program found it not to be cost effective, fur-
ther analysis of the results indicated that it be-
came cost effective with modest changes in
clinical or travel costs. Accordingly, costs of a
teledermatology program are likely to depend
on the situational and generalizable impacts of
telemedicine, and that decision makers need to
consider the relative roles of each. At the same
time, researchers may contribute by further an-
alyzing the determinants of clinical productiv-
ity in teledermatology and the relative magni-
tude of these when compared with the savings
from travel and the costs of technology.
Telepsychiatry presents a contrasting set of
insights when examined through this concep-
tualization of the sources of telemedicine costs.
Telepsychiatry has been shown to be feasible,
may increase access to care, and often is re-
ported cost effective. The unit of output in
telepsychiatry is the visit, but this is somewhat
ambiguous as a measure of treatment output.
At the same time, there is considerable latitude
in the resources used to provide telepsychiatry.
Moreover, telepsychiatry has lacked standard
models or guidelines for care, although several
detailed guidelines have been recently pub-
lished.
Consequently, it becomes difficult to deter-
mine how much or whether telemedicine
changes the productivity of the psychiatric clin-
ical process. Telepsychiatry is usually reported
as less expensive for patients when the cost of
travel and lost time are considered.33 This is es-
pecially apparent when care is provided to
prison populations, remote clinics, and other-
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wise isolated populations.34 Indeed, telepsy-
chiatry services have been estimated to be less
expensive, as expensive, or more expensive
than in-person services.35 The small size of
many programs may be a problem, and some
approaches to the delivery of telepsychiatry
have been reported be more cost-effective than
others.33
The implication of this economic interpreta-
tion of telemedicine findings is that telepsychi-
atry may be cost-effective, but the findings are
unclear. Certainly, RCT studies may provide
better evidence, but measurement issues ap-
pear to be a major barrier to drawing definitive
conclusions. Future studies of telepsychiatry
should focus on telepsychiatry outputs and the
changes in the mix and use of resources in the
clinical care process.
Cost impacts on disease management
Some telemedicine programs may be viewed
as having a direct effect on the process of 
maintaining health and well-being (referred to
by economists as the production of health)
rather than simply affecting access and effi-
ciency. Economic analyses from outside of
telemedicine have indicated that activities that
prevent illness are often far more cost-effective
than medical care treatments.36 Accordingly,
telemedicine interventions that reduce the use
of medical care through primary or secondary
prevention potentially could save costs that
might overshadow the effects on access alone.
The costs saved through telemedicine through
reduced travel to medical care needed in the
absence of the preventive activity likely would
pale in comparison.
Home telecare and telemonitoring may offer
significant cost savings in terms of health and
wellness. These applications may provide little
improvement in access to clinical treatment,
and they may not have a significant effect on
the cost-effectiveness of clinical care. But they
can change the need for care. Recent evidence
suggests that significant savings are possible
through the use of telehealth to diminish the
need for medical care.37,38 For example, a ran-
domized controlled trial of prenatal telehome-
care for high-risk pregnancies reported a re-
duction in hospital use.39 Subsequently, a
landmark RCT study of home telecare demon-
strated cost-savings through reduced utiliza-
tion.38 In this latter study, remote monitoring
and real-time video interactions reduced total
costs of care relative to those receiving tradi-
tional homecare. More recent studies further
provide evidence of the potential cost-effec-
tiveness of telemonitoring among congestive
heart failure and diabetic patients.37,38
Overall, a notable contrast has emerged in
the apparent success of telemonitoring and
home telecare cost-effectiveness studies, when
compared with the limited results from tele-
consultations.19,40,41 A number of explanations
for this difference seem plausible. Home tele-
care and telemonitoring occur outside estab-
lished medical facilities and are therefore less
likely burdened by historical overhead costs
that may or may not be necessary for other
types of telemedicine. This application may
represent a more targeted intervention of high-
risk patients with a narrowly defined technol-
ogy. These findings are likely to generate even
more high-quality research in this area.
On the other hand, it may also be, as some
economists have long argued,36 that more med-
ical care may not be as cost-effective as main-
taining or improving health. In this case, home
telecare may be benefiting from the underlying
opportunity in the production of health. If so,
telemedicine applications that further exploit
investment opportunities in wellness would
have a higher likelihood of success.
The contextual assessment of cost findings
Health economics concepts, such as produc-
tions functions, may improve the design and in-
terpretation of telemedicine cost analysis. Yet,
the interpretation and synthesis of cost evalua-
tions also requires an understanding of the de-
cision-making assumptions and environmental
context of the telemedicine activities that incur
costs. Here, this is defined as the contextual as-
sessment of the cost evaluation and includes
both the decision-making context as represented
in the “Cost Assessment Framework” and the
environmental context of the telemedicine pro-
gram that may impact its performance.
Cost evaluation findings on a telemedicine
activity depend on such decision-making
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specifics as the perspective, the target popula-
tion, and the decision time horizon. Contextual
factors, such as provider fee levels, equipment
costs, and health system efficiencies, may de-
termine the external validity of findings. Al-
though both the decision-making and environ-
mental context of findings may limit the
applicability of findings, an understanding and
even separate analysis of these factors may fa-
cilitate further synthesis of disparate findings.
For example, adjustments to local provider
costs may provide insights into observed dif-
ferences in study results.
This section examines issues pertaining to
contextual determinants of cost findings and
ways in which understanding the context fa-
cilitates the interpretation and synthesis of re-
sults. Also, some research strategies that may
address these contextual factors that can im-
prove telemedicine cost evaluations are con-
sidered.
Decision maker and information requirements
Existing telemedicine cost research and
analyses rarely discuss the decision-making ob-
jectives that would be supported by the results
of a specific study. Neither do they explicitly
define the informational needs of decision
makers who would use such results. Nonethe-
less, each of these is likely to have profound ef-
fects on the design of the study, methods of sta-
tistical inference, and the interpretation and
usefulness of study results.
Many evaluations performed in the United
States appear to define the research question 
so as to obtain cost-effectiveness information
needed for directly funded government health-
care delivery programs. But these seldom trans-
late easily to the decision-making needs of mar-
ket-driven institutions and third-party payers.
For example, researchers frequently rely only
on the societal perspective in evaluating costs
and benefits. All costs and all benefits are con-
sidered regardless of who pays the cost or gains
the benefit. However, private health-care insti-
tutional decision making will be based on a
narrower set of costs and benefits, often, within
the context of a business case that considers the
costs and benefits related to institutional ex-
penditures and revenues. A third-party insurer
will likely consider the costs and benefits quite
differently. An insurer is likely to be especially
interested in the effects of a reimbursement pol-
icy on its costs and revenues.
At the same time, and perhaps inconsis-
tently, the research designs in economic stud-
ies of telemedicine appear to focus on local de-
cision making, and do not address contextual
variables and measurements that facilitate ap-
plications in other settings. Hence, it is incum-
bent on the analyst of truly generalizable re-
search to address issues of comparability of
costs and benefits, external validity, and rele-
vance of research for various health-care deci-
sion-making or policy objectives.
At the same time, this does not imply that a
locally focused evaluation is of low quality, es-
pecially if it provides information needed for
decision making. The approach and findings
limit their range of applicability. For example,
differences in unit costs of inputs have been
found to affect CEA ratios among European
Union countries.42 An analysis by Drummond
also led him to conclude that it is difficult to
infer CEA results between countries. This prob-
lem becomes even more difficult if countries
vary in the resources used to produce a given
result.43,44
The dilemma is that costs and benefits of re-
search also have to be considered, and gener-
alization has a cost. The optimal trade-off
partly depends on the specific needs of deci-
sion-makers and the expected scope of gener-
alization of results.
Complexity of telemedicine interventions
Evaluating the costs and benefits of telemed-
icine depends on identifying the resource basis
used in producing telemedicine. Costs and ben-
efits may be defined largely through the de-
vices used, as in some telemonitoring. They
may be affected by various factors, including
sharing the technology for other functions and
an array of work processes and external orga-
nizational interactions, as in a community-
wide telepyschiatry program. Yet, precisely
how we specify the intervention sets the chal-
lenge in measuring costs and benefits. For ex-
ample, digital radiography is often cost-effec-
tive separate from it use in telemedicine. It
REARDON362
5690_10_p348-369  7/6/05  2:17 PM  Page 362
provides savings in the reduced cost of film
and related supplies as well as through fewer
lost images. But once the technology for digi-
tal radiography is available, the cost of the ad-
ditional systems to implement teleradiology is
dramatically reduced. Of course, the benefits
also become limited to gains from the electronic
exchange of radiography. Nonetheless, despite
increasingly widespread acquisition of digital
imaging systems, there appears to be no com-
prehensive estimate of the economic returns on
investment.45
The definition that distinguishes the inter-
vention from context may also delineate the po-
tential generalization of findings. For instance,
a narrowly defined intervention, such as a
telemedicine device, may be more consistently
identified, characterized for costs and benefits,
and reproduced in new settings. Modifications
or adjustments, such as in prices, may be
needed to apply results in a new context. These
are less likely to be a problem for decision mak-
ers. In contrast, the greatest challenge in ap-
plying economic evaluation methods is in pro-
grams that have ambiguous boundaries of
intervention and broadly defined or intangible
outputs.46 For example, it would be far more
challenging to identify clearly inputs and as-
sociated input costs and to track outcomes in a
broadly defined telehealth network. Similarly,
programs that rely on extensive and complex
interactions imbedded in organizational pro-
cesses present difficulties in measuring costs
and outcomes. On the other hand, telemedicine
interventions that deliver the greatest cost sav-
ings likely to be narrow and well defined, such
as monitoring of congestive heart failure pa-
tients, or home telecare.37,38
Methods for statistical inference
The study designs employed in economic
evaluations include decision analytic models, ob-
servational studies, and clinical trials. Observa-
tional studies are more prevalent in the litera-
ture. Prior to the mid-1990s, health-care cost
analyses often used clinical trial data on effec-
tiveness to develop a decision model for deter-
mining costs and benefits. Within the last decade,
several cost studies have been integrated with
RCTs, but the majority do not do so.47
Perhaps this evolution explains the apparent
preference for RCT or quasi-experimental de-
signs, and the growing number of RCT-based
studies. Nonetheless, these studies tend to rely
on comparative evaluations of program out-
come measures, and are mostly patterned after
the clinical trials of medical care research. The
presumed power of the RCT is that random-
ization of patients to telemedicine and tradi-
tional care settings assures unbiased compar-
isons in the use of resources and outcomes. This
is certainly the case when evaluating devices
such as tele-EKGs. Still, the requirements of
some research may suggest the use of alterna-
tive methods of inference, either in combina-
tion or as an alternative. This is because
telemedicine interventions are often complex
systems of devices and activities, the perfor-
mance of which significantly depends on con-
textual factors that are independent of the re-
search treatment.
RCT designs in telemedicine economic re-
search would be subject to significant external
validity threats from economic determinants
not controlled through randomized assign-
ment of patients.48 For example, telemedicine
interventions may involve extensive process
and behavioral changes that are affected by
health-care policy, local resources costs, re-
source costs, and incentives that are beyond the
boundary of the research randomization. De-
spite the use of randomized, controlled trials,
the systemic nature of the telemedicine pro-
duction process may easily be affected by ma-
jor contextual factors that will limit external 
validity of findings. Alternative, non-RCT pro-
cesses and concept models may be available to
reduce error variance and biased results. Se-
lectivity models that better address beneficiary
behaviors and policy maker needs when faced
with new technologies have proven useful in
other areas of health-care research. Techniques
that combine trial-based and observational
data, sample selection, and censored data esti-
mation are among current major development
across areas of health-care cost analysis.48
Consequently, the selection of the most ap-
propriate methods of inference in telemedicine
cost research depends on a range of multivari-
ate statistical techniques to improve the effi-
ciency of estimation and adjustment for selec-
ASSESSING TELEMEDICINE COSTS 363
5690_10_p348-369  7/6/05  2:17 PM  Page 363
tion bias. These approaches may be used as al-
ternatives or complements to RCT methods,
especially as a means of revealing logical con-
nections among inputs, context, and outputs
and in leveraging and the generality of find-
ings.
SUMMARY AND RECOMMENDATIONS
Lamenting the lack of information on
telemedicine cost analysis has become a stan-
dard preface to discussions of telemedicine
evaluation. An ample volume and variety of
explanations for the dearth of results are often
cited. These include small user populations,
rapidly changing technology, poor selection
and application of statistical and economic
methodologies, and inherent failings in avail-
able economic evaluation methodologies.15,18,26
Still, researchers express a growing optimism
in the value of telemedicine while government
and health-care decision makers from many
countries increasingly invest in telemedicine.
Assuming rational behavior among the stake-
holders, the evidence from these sentiments
suggests that more convincing data on the costs
and benefits of telemedicine exist. The incon-
gruity of formal assessments and decision-
maker behavior suggests the need for a more
careful design and assessments of current pro-
grams. The lack of convincing evaluations
partly may reflect inadequate analytic assess-
ment, integration, and synthesis of available
data.
Cost evaluations of telemedicine have been
undertaken in a diverse and global set of
health-care delivery settings. Studies represent
an economically heterogeneous set of pro-
grams and systems of care analyzed as discrete
intervention alternatives. As a result, study
data represent a large number of observations,
often with little apparent commonality, and the
integration of findings is arduous at best. A few
notable findings have been identified, but re-
sults are meager for any specific technology or
decision problem, and they are unlikely to pro-
vide much useful information. Yet, little atten-
tion has been paid to the unique methodolog-
ical considerations and potential strategies for
program cost evaluations. Economic and deci-
sion-making concepts provide a host of tools to
interpret and synthesize findings that appear
to have been overlooked. These provide added
insights into telemedicine program cost results
once integrated meaningfully.
This paper was aimed at understanding
available cost data, not simply from an assess-
ment of the aggregate validity of statistical es-
timates. Statistically valid findings are limited.
An attempt was made to use economic theory
to understand the fragmentary and sparse find-
ings. Nonetheless, an interpretation within an
economic theoretical structure and applied de-
cision-making framework provides additional
corroborating evidence on the efficiencies and
potential value of telemedicine. At the same
time, these assessments provide insights as to
potential design of telemedicine programs and
further cost analysis research.
This review of telemedicine cost studies sup-
ports previous conclusions on the potential net
savings to society through certain uses of
telemedicine. Populations in remote areas, in
prisons, or on ships may have reduced total
cost of care by accessing it through telemedi-
cine. But these reported gains in the cost-effec-
tiveness of telemedicine depend on the reduced
cost of access to care.
Distances and other barriers make the cost of
travel to obtain care inordinately high, and the
change in output with telemedicine has been
along the dimension of access as opposed to
changes in health. The relatively lower cost-to-
benefit performance of these programs de-
pends on changes in situational variables, such
as geography, as well as reductions in the cost
of information technology. Perhaps most im-
portantly, savings from the relatively favorable
cost performance of these programs may not
accrue to the payers of care. Hence, the health
plans on Europe, Canada, the U.S. Department
of Defense, and prisons that pay for access may
have incentives to provide this type of telemed-
icine. Otherwise, most U.S. plans do not pay
the costs of barriers to access, and in fact may
gain from these barriers.
On the other hand, generalizable telemedi-
cine savings from clinical care efficiencies, as
opposed to access savings, may be observed in
studies of specialty areas that have a potentially
modifiable clinical production process through
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telemedicine and that have a research design
that allows for the detection of the potential
gains. Cost evaluations are more likely to de-
tect improvements in clinical efficiencies if out-
puts are at least measured as episodes of care.
Both dermatology and psychiatry appear to
have the potential for clinical efficiencies
through telemedicine, but this is more clearly
accomplished in store-and-forward dermatol-
ogy where the process of care is most clearly
changed. In telepsychiatry, changes in pro-
cesses of care to take advantage of telemedicine
are less clearly measurable.
The greatest potential for cost savings from
telemedicine appears to be in its application in
the production of health or wellness. When
study outcomes are measured as health main-
tenance or wellness, as is usually done in home
care, potential savings from telemedicine ap-
pear to be much greater. In particular, this type
of telemedicine may be especially cost effective
for high-risk and specific types of chronically
ill patients.
The application of the economic concepts of
production and contextual analysis and syn-
thesis of cost-evaluation methodologies and
findings appear to make better use of the cost
literature. But the use of economic production
concepts and the cost-assessment frameworks
and the environmental determinants of pro-
gram performance may make their greatest con-
tribution in helping to define more innovative
future research. Areas of likely payoff are stud-
ies of self-selection into telemedicine programs,
adjustments for local health-care costs and sys-
tem efficiencies, and the impact of incentives on
specialties such as telepsychiatry where poten-
tial but difficult-to-measure changes in clinical
efficiencies may occur.
Generally, the need to integrate current costs
findings seems evident, and greater reliance on
economic and decision-making structures seems
desirable. Telemedicine technology is frequently
considered a “black box.” But telemedicine sys-
tems of care have important behavioral deter-
minants and effects that may both better un-
derstood and evaluated through economic and
health-care delivery concepts and through al-
ternative approaches to assessing causality. Al-
though the specific choice of methods of infer-
ence and design depend on specific research
study needs and constraints, more flexible meth-
ods of establishing causality often may be justi-
fied and sometimes needed so as to aid inter-
pretation and generalization of findings. Hence,
a strict reliance on randomized, controlled trials
for cost analysis is questionable.
Finally, telemedicine cost evaluation occu-
pies a difficult divide between evaluation hav-
ing a focus on providing information for local
decision makers, and a focus on providing gen-
eralizable estimates of cost impact. General
findings are needed to improve effectiveness
and reduce costs to the broader community of
decision makers; however, these likely have re-
search costs and trade-offs that may not im-
mediately benefit a researcher’s constituency.
Consensus guidelines and best practices on
costs provide common benefits to cost research,
but they are unlikely to be supported by indi-
vidual research or provider groups. Both the
support and expansion of the common research
contributions provided by guidelines and the
development of strategies for addressing the
balance of the private and shared-cost research
costs and benefits question may make the
greatest single contribution in enhancing the
value of telemedicine cost literature.
APPENDICES
Appendix 1: Methods of health-care 
cost analysis
Cost–benefit analysis (CBA): CBA remains the
paradigm for conceptualizing cost analysis,
and it continues to serve as the ideal in defin-
ing opportunity costs and the valuation of ben-
efits. In classic cost–benefit analysis, all input
costs and benefits are transformed into mone-
tary terms, such as dollars, as would be the case
for individual decision-making in the market.
The operational impediments to CBA are well
documented for problems dealing with per-
sonal health-care services where the most sig-
nificant issue may be the lack of generally ac-
cepted methods for translating benefits into
dollars. Although various willingness-to-pay
methodologies have been used for CBA of
health services programs, ongoing public and
economic debate over their use makes them un-
appealing.49
ASSESSING TELEMEDICINE COSTS 365
5690_10_p348-369  7/6/05  2:17 PM  Page 365
Cost-effectiveness analysis (CEA/CUA): The de-
velopment of CEA was stimulated by the dis-
comfort in CBA when translating medical out-
comes such as years of life or a change in blood
pressure into monetary values. Whereas costs
are monetary in a CEA, outcomes are 
reported in nonmonetary terms. In personal
health-care, these terms are expressed in such
intermediate metrics as the outcomes of blood
pressure or recidivism or such longer-term out-
comes as quality-adjusted life years (QALYs),
where a quality year may be partially defined
by health.4,7 A CUA is particular type of CEA
that uses QALYs as an outcome. The resulting
cost per QALY provides a common currency
that is especially helpful for comparisons
among disparate technologies.5
The objective in a typical CUA is to estimate
the number of quality-adjusted life years pro-
duced through monetary expenditures on spe-
cific health-care interventions. QALY effects of
an intervention are captured in the denomina-
tor of the ratio, whereas changes in resource
use for an intervention are captured in the nu-
merator in monetary terms. A result, for ex-
ample, may be that a program costs $10,000 per
each additional life year. CUA ratios may be
compared among a few alternatives or com-
pared with a standard set of interventions, as
from a league table that lists the cost per life
year for a wide range of projects.50 Guidelines
or “rules of thumb” for accepting interventions
with CUA ratios, for example, of less than
$100,000 per life-year, have been a subject of
extensive health-care research.24
The Panel on Cost Effectiveness in Health
and Medicine (United States Public Health Ser-
vice) advocates use of the CUA form of cost-ef-
fectiveness analysis.4
Cost-minimization analysis (CMA): Cost-mini-
mization analysis (CMA) is essentially a cost-
savings analysis. That is, the focus of the anal-
ysis is on finding the alternative with the lowest
cost; for example, the cheapest way to produce
a medical visit or to treat a case. To the extent
that telemedicine may not change an immedi-
ate health outcome and constitutes only a
change in process, then use of CMA is justified.
On the other hand, if benefits do change, in-
formation is lost and important findings may
be overlooked when using CMA rather than
CBA or CEA.
Return on investment (ROI): In its narrowest
definition, return on investment is defined as a
mathematical relationship, where the total
monetary benefit from an investment is di-
vided by initial and subsequent costs.47 ROI is
then stated as a percentage or ratio, and it pro-
vides a concise summary of factors that define
the gains from an investment. As a good com-
parative summary of the profitability of an in-
vestment, this metric is especially well suited
for for-profit organizational decision making.
Yet, ROI is not usually cited or discussed in
health-care economic cost research because it is
viewed as organizational expenditures as op-
posed to opportunity costs, and its traditional
methods do not include quantifying nonmon-
etary costs and benefits. Moreover, the ROI
problem has been focused on capital invest-
ments for production, as opposed to consump-
tion goods. That is, the organizational decision
maker’s interest is on the firm’s monetary re-
turns from an investment as opposed to the to-
tal value of benefits provided to a consumer.
Nonetheless, the term ROI increasingly is be-
ing applied to all cost-and-benefit methods.51
The broader definition encourages a compari-
son of an investment’s total value and costs, in-
cluding the consideration of nonmonetary ben-
efits.47 For example, U.S. government guidance
on information technology investments now
defines ROI as encompassing the collection of
quantitative cost/benefit methods, including
CEA.47 But this question on the definition of
ROI may not be clear, but broadening the con-
cept has extended the focus of government an-
alysts concerned with organizational decision-
making tradeoffs, benefits, and costs. Then,
while these government organizational expen-
ditures still may not represent opportunity
costs from the societal perspective, they repre-
sent opportunity costs within the framework of
an organizational budget. Moreover, resulting
cost analysis approaches may be applied
equally to incorporate nonmarket and oppor-
tunity cost concepts in private business orga-
nization decision making, especially analyses
and policies of private health-care organiza-
tions.
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Functional economic analysis (FEA): FEA is a
variation of cost analysis developed to accom-
modate the needs of information technology
and organizational decision making.52,53 In-
formation technology products, including
telemedicine, may be defined as sets of func-
tions or capabilities as opposed to hardware,
software, or a physical system.53–55 FEA fo-
cuses on the costs of the functions or capabili-
ties that facilitate specific health-care objec-
tives, such as providing medical care services
or improved access to care. Thus, costs and
benefits are associated with specific functions
or information capabilities, such as providing
an electronic medical record capability. Orga-
nizations may define decision-maker responsi-
bilities and workflows that support functions
to enable identification of costs.
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Method Characteristics Disadvantages
Cost-benefit analysis Paradigm for cost analyses No generally accepted methods of 
(CBA) Defines opportunity costs quantifying many benefits as dollars
Optimizes social welfare Reluctance to express value of health or 
Broad comparisons possible life in monetary terms
Cost-effectiveness Outcomes reported in non-monetary terms Inability to compare findings across 
analysis/cost utility Outcomes may be expressed as QALYs health-care areas.
analysis (CEA/CUA) Preferred by U.S. Public Health Service Baseline
consensus panel Generalizability of utility estimates
Benchmarks and comparisons available in Costs of collecting utility data
major online databases (http://www. Findings indicating that utility data 
hsph.harvard.edu/cearegistry/) usually does not change a result
Cost-minimization Lowest cost option sought May overlook changes in benefits
analysis (CMA) Less demanding data requirements
Return on investment Mathematical relationship: monetary Better suited to for-profit decision making
(ROI) benefit divided by initial and Overlooks nonmonetary benefits
subsequent costs Focuses on capital investments for 
Facilitates investment analyses production, not consumption
Functional economic Facilitates analyses of information costs Need for conceptual development of 
analysis (FEA) and benefits functions
Benefits and costs derived for information Generalizability
capabilities and functions
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